Literature DB >> 18980959

Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality.

Stephen J Onufrak1, Antonio Bellasi, Francesca Cardarelli, Viola Vaccarino, Paul Muntner, Leslee J Shaw, Paolo Raggi.   

Abstract

Serum phosphorus levels in the general population have been reported to be associated with cardiovascular morbidity and mortality and increased carotid intima-media thickness. The authors examined gender heterogeneity in the association of phosphorus with all-cause mortality and incident coronary artery disease using data from the Atherosclerosis Risk in Communities Study (1987-2001). Baseline phosphorus levels were higher in women and were associated differently among men and women with traditional atherosclerosis risk factors such as age, low density lipoprotein cholesterol, diabetes mellitus, and hypertension. In a multivariable-adjusted model, men in the highest quintile of serum phosphorus level (>3.8 mg/dL) had an increased mortality rate (hazard ratio = 1.45, 95% confidence interval: 1.12, 1.88), while women did not (hazard ratio = 1.18, 95% confidence interval: 0.89, 1.57). The multivariable likelihood ratio test of effect modification by gender was significant at alpha = 0.1 (P = 0.085) for all-cause mortality. Although the associations of phosphorus with coronary artery disease also appeared to differ substantially by gender, the multivariable test for effect modification suggested that the difference was consistent with random variation (P = 0.195). These results suggest the need for further investigation into gender differences in the contribution of mineral metabolism to cardiovascular disease in the general population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18980959      PMCID: PMC2720702          DOI: 10.1093/aje/kwn285

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  30 in total

1.  Direct method for determining inorganic phosphate in serum with the "CentrifiChem".

Authors:  J A Daly; G Ertingshausen
Journal:  Clin Chem       Date:  1972-03       Impact factor: 8.327

2.  Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D.

Authors:  H Rickers; C Christiansen; P Christensen; M Christensen; P Rødbro
Journal:  Nephron       Date:  1985       Impact factor: 2.847

3.  Phosphate regulation of vascular smooth muscle cell calcification.

Authors:  S Jono; M D McKee; C E Murry; A Shioi; Y Nishizawa; K Mori; H Morii; C M Giachelli
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

4.  Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Eric W Young; Takashi Akiba; Justin M Albert; James T McCarthy; Peter G Kerr; David C Mendelssohn; Michel Jadoul
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

5.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.

Authors:  Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

6.  Suppression of calcific fibrous-fatty plaque formation in rabbits by agents not affecting elevated serum cholesterol levels. The effect of thiophene compounds.

Authors:  C T Chan; H Wells; D M Kramsch
Journal:  Circ Res       Date:  1978-07       Impact factor: 17.367

7.  Phosphorus levels are associated with subclinical atherosclerosis in the general population.

Authors:  Stephen J Onufrak; Antonio Bellasi; Leslee J Shaw; Charles A Herzog; Francesca Cardarelli; Peter W Wilson; Viola Vaccarino; Paolo Raggi
Journal:  Atherosclerosis       Date:  2008-02-21       Impact factor: 5.162

8.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Authors:  Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

9.  Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

Authors:  Yutaka Takahashi; Araki Tanaka; Tsukasa Nakamura; Tsutomu Fukuwatari; Katsumi Shibata; Noriaki Shimada; Isao Ebihara; Hikaru Koide
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612

Review 10.  Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences.

Authors:  Kamyar Kalantar-Zadeh; T Alp Ikizler; Gladys Block; Morrel M Avram; Joel D Kopple
Journal:  Am J Kidney Dis       Date:  2003-11       Impact factor: 8.860

View more
  35 in total

1.  Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in Men study.

Authors:  Jerry Meng; Claes Ohlsson; Gail A Laughlin; Michel Chonchol; Christina L Wassel; Osten Ljunggren; Magnus K Karlsson; Dan Mellstrom; Eric S Orwoll; Elizabeth Barrett-Connor; Joachim H Ix
Journal:  Kidney Int       Date:  2010-06-09       Impact factor: 10.612

2.  Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.

Authors:  Darbie Maccubbin; Diane Tipping; Olga Kuznetsova; William A Hanlon; Andrew G Bostom
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 8.237

3.  Hyperphosphate-Induced Myocardial Hypertrophy through the GATA-4/NFAT-3 Signaling Pathway Is Attenuated by ERK Inhibitor Treatment.

Authors:  Yao-Lung Liu; Chiu-Ching Huang; Chiz-Chung Chang; Che-Yi Chou; Shih-Yi Lin; I-Kuan Wang; Dennis Jine-Yuan Hsieh; Gwo-Ping Jong; Chih-Yang Huang; Chao-Min Wang
Journal:  Cardiorenal Med       Date:  2015-01-27       Impact factor: 2.041

Review 4.  Mineral metabolism and cardiovascular disease in CKD.

Authors:  Hideki Fujii; Nobuhiko Joki
Journal:  Clin Exp Nephrol       Date:  2017-01-06       Impact factor: 2.801

5.  Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease.

Authors:  Eric N Taylor; Eric B Rimm; Meir J Stampfer; Gary C Curhan
Journal:  Am Heart J       Date:  2011-05       Impact factor: 4.749

6.  Associations of socioeconomic status and processed food intake with serum phosphorus concentration in community-living adults: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Orlando M Gutiérrez; Ronit Katz; Carmen A Peralta; Ian H de Boer; David Siscovick; Myles Wolf; Ana Diez Roux; Bryan Kestenbaum; Jennifer A Nettleton; Joachim H Ix
Journal:  J Ren Nutr       Date:  2012-01-03       Impact factor: 3.655

7.  Sex differences in risk factors for coronary artery disease and stroke in men and women aged 45-65 years.

Authors:  D Hochner-Celnikier; T Chajek-Shaul; O Manor
Journal:  Heart Asia       Date:  2013-10-26

8.  Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults.

Authors:  Bhupesh Panwar; Suzanne E Judd; Virginia G Wadley; Nancy S Jenny; Virginia J Howard; Monika M Safford; Orlando M Gutiérrez
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

9.  Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study.

Authors:  Georges Saab; Mary A Whooley; Nelson B Schiller; Joachim H Ix
Journal:  Am J Kidney Dis       Date:  2010-06-26       Impact factor: 8.860

10.  Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.

Authors:  Himiko Sugimoto; Tetsuya Ogawa; Yuko Iwabuchi; Kuniaki Otsuka; Kosaku Nitta
Journal:  Int Urol Nephrol       Date:  2013-01-25       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.